カテゴリー： MarketsandMarkets, 世界, 産業機械/建設

白血球除去の世界市場予測（～2028）：製品別、白血球アフェレーシス別、疾患別、用途別、エンドユーザー別、地域別

◆英語タイトル：Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to 2028

MarketsandMarketsが発行した調査報告書（MD6538-23）◆商品コード：MD6538-23
◆発行会社（リサーチ会社）：MarketsandMarkets
◆発行日：2023年8月31日
◆ページ数：321
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥742,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥997,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,222,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

"世界の白血球除去市場は、2023年の7,000万米ドルから2028年には1億米ドルに達すると予測され、CAGRは8.3％"
白血球パックの世界市場は、2023年の2億米ドルから2028年には1億2000万米ドルに達すると予測され、CAGRは38.1％です。白血病患者が世界的に増加し、臨床試験やその他の研究用途でロイコパックのニーズが高まっているため、白血球除去市場は予測期間中に成長する見込みです。

"研究用途が白血球除去市場でより大きなシェアを占める"
用途別に見ると、白血球除去市場は研究用途と治療用途に区分されます。2022年の白血球除去市場では、研究用途分野がより大きなシェアを占めています。細胞ベースの免疫療法の発展や、医薬品開発における白血球由来の初代細胞に対する需要の高まりは、予測期間中の白血球療法製品市場の成長を促進する主な要因の一部です。

"学術・研究機関セグメントが白血球パック市場で最大シェアを占める"
エンドユーザー別に見ると、ロイコパクス市場は学術＆研究機関、製薬＆バイオテクノロジー企業、受託研究機関に区分されます。2022年には、学術・研究機関セグメントが白血球除去市場で最大のシェアを占めました。細胞ベースのがん治療に関する研究を実施するための産学連携が増加していることが、このエンドユーザー分野の成長を牽引しています。

"アジア太平洋は予測期間中最高のCAGRで成長"
2022年、アジア太平洋は予測期間中最高のCAGRで成長するでしょう。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。CAR-T細胞療法研究の増加、中国における製薬・バイオテクノロジー企業や研究機関の増加などが、市場成長を促進する要因のひとつです。2022年には、中国がアジア太平洋のロイコパックス市場で最大のシェアを占めました。中国のシェアが大きいのは、同国に多くの細胞免疫療法企業が存在することが主な理由です。

白血球除去（ロイカフェレシス）製品市場における主要参入企業のプロファイルの内訳は以下の通りです：供給側
- 企業タイプ別（供給側） ティア1：35％、ティア2：30％、ティア3：35％
- 役職別 Cレベル：30％、ディレクターレベル：30％、その他：40％
- 地域別 北米：45％、ヨーロッパ：25％、アジア太平洋：20％、その他の地域：10 ％

ロイコパックス市場における主要参入企業プロファイルの内訳は以下の通りです：供給側
- 企業タイプ別（供給側） ティア1：44％、ティア2：36％、ティア3：20％
- 役職別 Cレベル：44％、ディレクターレベル：33％、その他：23％
- 地域別 北米：40％、ヨーロッパ：25％、アジア太平洋：20％、その他の地域：15％

白血球除去市場における主要企業は、Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US)などがあります。

調査範囲 ：
当レポートでは、白血球除去市場を分析し、製品、地域など様々なセグメントに基づいて市場規模や今後の成長可能性を推計することを目的としています。また、本市場における主要企業の企業プロフィール、製品提供、最新動向、主要市場戦略とともに競合分析も掲載しています。

レポートを購入する理由：
本レポートは、白血球除去市場全体とサブセグメントにおける収益数の最も近い近似値に関する情報を提供し、本市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、および機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（白血病の罹患率および有病率の上昇、献血数の増加、臨床研究におけるロイコパックの需要の増加）、阻害要因（治療用白血球療法およびロイコパックの高コスト、厳しいドナー募集基準、治療用白血球療法に伴う合併症）、白血球療法市場の成長に影響を与える機会（小児患者に対する白血球療法、学術機関、製薬・バイオテクノロジー企業、および大手企業からの投資を伴う新興国）、および課題（新興国における輸血の安全性）の分析を行っています。
- 製品開発/イノベーション：白血球除去市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察を掲載しています。
- 市場開発：タイプ別、用途別、エンドユーザー別、地域別の有利な新興市場に関する包括的情報を提供します。
- 市場の多様化：世界の白血球療法市場における新製品や製品の強化、成長地域、最近の開発、投資に関する詳細な情報を提供します。
- 競争力の評価：Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany)など主要企業の市場シェア、成長戦略、製品展開などを詳細に評価しています。

1.イントロダクション
2.調査方法
3.エグゼクティブサマリー
4.プレミアムインサイト
5.市場概要
6.白血球除去の市場分析：種類別
7.白血球除去の市場分析：用途別
8.白血球除去の市場分析：エンドユーザー別
9.白血球アフェレーシスの市場分析：種類別
10.白血球アフェレーシスの市場分析：疾患別
11.白血球アフェレーシスの市場分析：エンドユーザー別
12.白血球除去の市場分析：地域別
13.競争状況
14.企業情報
15.付録

❖ レポートの目次 ❖

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 38
1.2.1 TYPE 38
1.2.2 APPLICATION 38
1.2.3 END USER 38
1.2.4 INCLUSIONS AND EXCLUSIONS 39
1.3 MARKET SCOPE 40
1.3.1 MARKETS COVERED 40
1.3.2 YEARS CONSIDERED 41
1.4 CURRENCY CONSIDERED 41
TABLE 1 STANDARD CURRENCY CONVERSION RATES 41
1.5 STAKEHOLDERS 41
1.6 SUMMARY OF CHANGES 42
1.7 RECESSION IMPACT 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
FIGURE 1 RESEARCH DESIGN 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Key data from secondary sources 45
2.1.2 PRIMARY DATA 45
FIGURE 2 PRIMARY SOURCES 46
2.1.2.1 Key data from primary sources 47
2.1.2.2 Insights from primary experts 48
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET) 48
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET) 49
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS PRODUCTS MARKET) 49
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET) 50
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKOPAKS MARKET) 50
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS PRODUCTS MARKET 51
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 51
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2022) 52
FIGURE 10 REVENUE ANALYSIS OF TOP FOUR COMPANIES: LEUKAPHERESIS PRODUCTS MARKET (2022) 52
FIGURE 11 DEMAND-SIDE APPROACH: LEUKAPHERESIS PRODUCTS MARKET (2022) 53
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 55
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 56
FIGURE 14 TOP-DOWN APPROACH 56
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET 57
FIGURE 15 VOLUME ESTIMATION OF LEUKOPAKS MARKET 58
FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET) 59
FIGURE 17 TOP-DOWN APPROACH 59
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 18 MARKET DATA TRIANGULATION METHODOLOGY 61
2.5 MARKET SHARE ANALYSIS 61
2.6 RESEARCH ASSUMPTIONS 62
2.7 RISK ASSESSMENT 62
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS 62
2.8 METHODOLOGY-RELATED LIMITATIONS 62
2.9 RECESSION IMPACT ANALYSIS 63
3 EXECUTIVE SUMMARY 64
FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 64
FIGURE 20 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 65
FIGURE 21 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 65
FIGURE 22 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 66
FIGURE 23 LEUKOPAKS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 67
FIGURE 24 LEUKOPAKS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 67
FIGURE 25 LEUKOPAKS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 68
FIGURE 26 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET 69
FIGURE 27 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET 70
4 PREMIUM INSIGHTS 71
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW 71
FIGURE 28 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET 71
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY 72
FIGURE 29 DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2022 72
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX 72
FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 72
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX 73
FIGURE 31 NORTH AMERICA DOMINATED MARKET IN 2022 73
4.5 LEUKOPAKS MARKET: OVERVIEW 73
FIGURE 32 RISING DEMAND FOR LEUKOPAKS FOR USE IN RESEARCH APPLICATIONS TO DRIVE MARKET 73
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY 74
FIGURE 33 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2022 74
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX 75
FIGURE 34 CHINA TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD 75
4.8 LEUKOPAKS MARKET: REGIONAL MIX 75
FIGURE 35 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 75
5 MARKET OVERVIEW 76
5.1 INTRODUCTION 76
5.2 MARKET DYNAMICS 76
FIGURE 36 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 76
5.2.1 DRIVERS 77
5.2.1.1 Rising incidence and prevalence of leukemia 77
FIGURE 37 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020–2040) 77
FIGURE 38 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020–2040) 78
5.2.1.2 Increasing blood donation 78
5.2.1.3 Growing demand for leukopaks in clinical research 79
FIGURE 39 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009–2020 79
FIGURE 40 NUMBER OF CAR-T THERAPY CLINICAL TRIALS: US VS. CHINA, 2022 79
5.2.2 RESTRAINTS 80
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks 80
TABLE 3 COST OF LEUKOPAKS, BY TYPE 80
5.2.2.2 Stringent donor recruitment criteria 81
TABLE 4 DONOR SELECTION CRITERIA 81
TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS 82
5.2.2.3 Dearth of skilled professionals 82
5.2.2.4 Complications associated with therapeutic leukapheresis 82
5.2.2.5 Long duration of procedure 82
5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement 83
5.2.3 OPPORTUNITIES 83
5.2.3.1 Growing focus on leukapheresis for pediatric patients 83
5.2.3.2 Increasing investments in CAR-T therapies in emerging economies 84
5.2.3.3 Gaps in current leukapheresis technologies 84
5.2.4 CHALLENGES 84
5.2.4.1 Concerns related to safety of blood transfusion in emerging economies 84
5.3 PORTER’S FIVE FORCES ANALYSIS 85
FIGURE 41 PORTER’S FIVE FORCES ANALYSIS: LEUKAPHERESIS MARKET 85
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.3.1 THREAT FROM NEW ENTRANTS 86
5.3.2 THREAT FROM SUBSTITUTES 86
5.3.3 BARGAINING POWER OF SUPPLIERS 86
5.3.4 BARGAINING POWER OF BUYERS 87
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.4 INDUSTRY TRENDS 87
5.4.1 INCREASING COLLABORATIONS BETWEEN PHARMA AND BIOTECH COMPANIES 87
TABLE 7 RECENT DEVELOPMENTS RELATED TO CAR-T THERAPY 88
5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS 89
5.5 TECHNOLOGY ANALYSIS 89
5.5.1 KEY TECHNOLOGIES 89
5.5.1.1 Centrifugal-based leukapheresis 89
5.5.1.2 Membrane-based leukapheresis 90
TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION 90
5.5.2 EMERGING TECHNOLOGIES 90
5.5.2.1 Adsorption-based leukapheresis 90
5.5.2.2 Microfluidic devices for leukapheresis 91
5.5.2.3 Integration of AI in leukapheresis treatment 91
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET) 92
TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS 92
TABLE 10 ASP OF MOBILIZED LEUKOPAKS 93
TABLE 11 ASP OF MOBILIZED ISOLATED CELLS 93
5.7 KEY CONFERENCES AND EVENTS, 2023–2024 94
TABLE 12 LEUKAPHERESIS MARKET: CONFERENCES AND EVENTS 94
5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 96
5.8.1 NORTH AMERICA 96
5.8.1.1 US 96
5.8.1.2 Canada 96
5.8.2 EUROPE 96
5.8.3 ASIA PACIFIC 97
5.8.3.1 Japan 97
5.8.3.2 China 97
5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET) 100
5.10.1 US 100
TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS 101
5.10.2 EUROPE 101
5.10.3 JAPAN 101
5.10.4 INDIA 102
5.11 VALUE CHAIN ANALYSIS 103
FIGURE 42 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS) 103
5.12 SUPPLY CHAIN ANALYSIS 104
FIGURE 43 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN 105
5.13 ECOSYSTEM ANALYSIS 105
FIGURE 44 LEUKAPHERESIS MARKET: ECOSYSTEM MAP 105
TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM 106
5.14 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS 107
5.15 PATENT ANALYSIS 107
5.15.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET 107
FIGURE 45 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2019–AUGUST 2023 108
5.15.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET 108
FIGURE 46 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2019–AUGUST 2023 108
5.15.3 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS 109
FIGURE 47 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023 109
5.15.4 TOP APPLICANTS FOR LEUKOPAK PATENTS 109
FIGURE 48 TOP APPLICANTS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023 109
5.15.5 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS MARKET PATENTS 110
FIGURE 49 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2019–AUGUST 2023 110
FIGURE 50 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023 110
5.15.6 TOP PATENT APPLICANTS/OWNERS 111
FIGURE 51 TOP APPLICANTS AND OWNERS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023 111
FIGURE 52 TOP APPLICANTS AND OWNERS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023 112
TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: MAJOR PATENTS (2020–2022) 113
TABLE 21 LEUKOPAKS MARKET: MAJOR PATENTS (2019–2022) 115
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 117
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 117
FIGURE 53 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 117
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 117
5.16.2 BUYING CRITERIA 117
FIGURE 54 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 117
TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS 118
5.17 CASE STUDIES 118
TABLE 24 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 118
TABLE 25 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 119
5.18 ADJACENT MARKET ANALYSIS 119
5.18.1 PLASMA FRACTIONATION MARKET 119
FIGURE 55 PLASMA FRACTIONATION MARKET OVERVIEW 119
5.18.2 APHERESIS MARKET 120
FIGURE 56 APHERESIS MARKET OVERVIEW 120
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE 121
6.1 INTRODUCTION 122
TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 27 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
6.2 DISPOSABLES 123
6.2.1 RECURRENT DEMAND TO BOOST SEGMENT 123
TABLE 28 LEUKOREDUCTION FILTER MANUFACTURERS 123
TABLE 29 LEUKAPHERESIS COLUMN AND CELL SEPARATOR MANUFACTURERS 124
TABLE 30 DISPOSABLES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
6.3 DEVICES 125
TABLE 31 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 32 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
6.3.1 CENTRIFUGAL DEVICES 127
6.3.1.1 Increasing installation in hospitals to drive market 127
TABLE 33 CENTRIFUGAL DEVICES AVAILABLE 128
TABLE 34 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.3.2 MEMBRANE SEPARATORS 129
6.3.2.1 Difficulty in separating large volumes of plasma to limit market 129
TABLE 35 MEMBRANE SEPARATORS AVAILABLE 130
TABLE 36 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
 
7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION 131
7.1 INTRODUCTION 132
TABLE 37 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
7.2 RESEARCH APPLICATIONS 132
7.2.1 GROWING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT 132
TABLE 38 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES 132
TABLE 39 RESEARCH APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
7.3 THERAPEUTIC APPLICATIONS 134
7.3.1 RISING ADOPTION OF LEUKAPHERESIS FOR LEUKEMIA TREATMENT TO FUEL MARKET 134
TABLE 40 THERAPEUTIC APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER 135
8.1 INTRODUCTION 136
TABLE 41 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 136
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 136
8.2.1 INCREASING BLOOD DONATION TO DRIVE MARKET 136
TABLE 42 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
8.3 ACADEMIC & RESEARCH INSTITUTES 138
8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET 138
TABLE 43 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 139
8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT 139
TABLE 44 PHARMA-BIOTECH COMPANIES DEVELOPING CAR-T CELL TECHNOLOGIES 139
TABLE 45 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
8.5 HOSPITALS & TRANSFUSION CENTERS 141
8.5.1 GROWING NEED FOR TRANSFUSIONS TO PROPEL MARKET 141
TABLE 46 HOSPITALS & TRANSFUSION CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
9 LEUKOPAKS MARKET, BY TYPE 143
9.1 INTRODUCTION 144
TABLE 47 LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 48 LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
9.2 MOBILIZED LEUKOPAKS 145
9.2.1 INCREASING USE IN CLINICAL RESEARCH TO DRIVE MARKET 145
TABLE 49 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS 146
TABLE 50 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 51 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS) 147
9.3 NON-MOBILIZED LEUKOPAKS 148
9.3.1 LOW COST TO PROPEL MARKET 148
TABLE 52 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS 148
TABLE 53 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 148
TABLE 54 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 149
TABLE 55 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 56 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS) 150
9.4 DISEASED LEUKOPAKS 150
9.4.1 RISING USE FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO BOOST MARKET 150
TABLE 57 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 58 DISEASED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS) 151
9.5 ISOLATED PBMCS 152
9.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET 152
TABLE 59 IMMUNE CELL TYPES AND TARGETED DISEASES 152
TABLE 60 ISOLATED PBMCS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 61 ISOLATED PBMCS MARKET, BY REGION, 2021–2028 (UNITS) 153
10 LEUKOPAKS MARKET, BY INDICATION 154
10.1 INTRODUCTION 155
FIGURE 57 NUMBER OF GLOBAL CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CELLS 155
TABLE 62 LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 156
10.2 ACUTE LYMPHOCYTIC LEUKEMIA 157
10.2.1 RISING INCIDENCE OF DISEASE TO DRIVE MARKET 157
TABLE 63 ACUTE LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
10.3 MULTIPLE MYELOMA 158
10.3.1 RISING DIAGNOSIS RATE TO FUEL SEGMENT 158
FIGURE 58 INCIDENCE OF MULTIPLE MYELOMA IN 2020 159
TABLE 64 MULTIPLE MYELOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
10.4 NON-HODGKIN’S LYMPHOMA 160
10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET 160
TABLE 65 NON-HODGKIN’S LYMPHOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA 161
10.5.1 RISING NUMBER OF CASES TO PROPEL MARKET 161
TABLE 66 CHRONIC LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 162
10.6 PANCREATIC CANCER 162
10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT 162
FIGURE 59 INCIDENCE OF PANCREATIC CANCER IN 2020 163
TABLE 67 PANCREATIC CANCER: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
10.7 HEPATOCELLULAR CARCINOMA 164
10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT 164
TABLE 68 HEPATOCELLULAR CARCINOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
10.8 OTHER INDICATIONS 165
TABLE 69 OTHER INDICATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 166
11 LEUKOPAKS MARKET, BY END USER 167
11.1 INTRODUCTION 168
TABLE 70 LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 168
11.2 ACADEMIC & RESEARCH INSTITUTES 168
11.2.1 INCREASING INDUSTRY−ACADEMIC RESEARCH PARTNERSHIPS TO DRIVE MARKET 168
TABLE 71 ACADEMIC & RESEARCH INSTITUTES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 169
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 169
11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT TO PROPEL MARKET 169
FIGURE 60 PERCENTAGE OF GLOBAL CAR-T DRUGS IN US AND CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT 170
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 170
11.4 CONTRACT RESEARCH ORGANIZATIONS 171
11.4.1 INCREASING CLINICAL TRIAL SPONSORSHIP TO DRIVE MARKET 171
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
12 LEUKAPHERESIS MARKET, BY REGION 172
12.1 INTRODUCTION 173
FIGURE 61 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 173
TABLE 74 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 174
FIGURE 62 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 174
TABLE 75 LEUKOPAKS MARKET, BY REGION, 2021–2028 (USD MILLION) 175
12.2 NORTH AMERICA 175
12.2.1 RECESSION IMPACT: NORTH AMERICA 175
FIGURE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 176
TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 78 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 79 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178
TABLE 80 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 178
TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 82 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 83 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 179
TABLE 84 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 180
12.2.2 US 180
12.2.2.1 Presence of leading pharmaceutical and biotechnology companies to drive market 180
TABLE 85 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG) 180
TABLE 86 US: KEY MACROINDICATORS 181
TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 88 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 89 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 90 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 182
TABLE 91 US: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 92 US: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 183
TABLE 93 US: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 183
12.2.3 CANADA 183
12.2.3.1 Rising prevalence of blood cancer to stimulate market growth 183
TABLE 94 CANADA: KEY MACROINDICATORS 184
TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 96 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 97 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 98 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 185
TABLE 99 CANADA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 100 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 186
TABLE 101 CANADA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 187
 
12.3 EUROPE 187
12.3.1 RECESSION IMPACT: EUROPE 188
FIGURE 64 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 189
TABLE 102 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 104 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 105 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 106 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
TABLE 107 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 108 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 109 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 193
TABLE 110 EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 193
12.3.2 UK 193
12.3.2.1 Rising awareness of cell-based therapies to propel market 193
TABLE 111 UK: KEY MACROINDICATORS 194
TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 113 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 114 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 115 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 195
TABLE 116 UK: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 117 UK: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 196
TABLE 118 UK: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 197
12.3.3 GERMANY 197
12.3.3.1 Increasing research on cancer immunotherapies to boost market 197
TABLE 119 GERMANY: KEY MACROINDICATORS 197
TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 121 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 122 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 123 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 199
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 125 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 200
TABLE 126 GERMANY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 200
12.3.4 SPAIN 200
12.3.4.1 Rising focus on development of novel CAR-T cell therapies to fuel market 200
TABLE 127 SPAIN: KEY MACROINDICATORS 201
TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 129 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 130 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 202
TABLE 131 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 202
TABLE 132 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 133 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 203
TABLE 134 SPAIN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 203
12.3.5 FRANCE 203
12.3.5.1 Government healthcare initiatives to drive market 203
TABLE 135 FRANCE: KEY MACROINDICATORS 204
TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 137 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 138 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 139 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 205
TABLE 140 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 141 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 206
TABLE 142 FRANCE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 206
12.3.6 ITALY 206
12.3.6.1 Increasing adoption of cell-based therapies to boost market 206
TABLE 143 ITALY: COMMERCIAL CAR-T CELL THERAPIES APPROVED BY EMA (2022) 207
TABLE 144 ITALY: KEY MACROINDICATORS 207
TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 146 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 147 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 208
TABLE 148 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 209
TABLE 149 ITALY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 150 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 210
TABLE 151 ITALY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 210
12.3.7 REST OF EUROPE 210
TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 153 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 154 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 212
TABLE 155 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 212
TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 157 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 213
TABLE 158 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 213
12.4 ASIA PACIFIC 214
12.4.1 RECESSION IMPACT: ASIA PACIFIC 214
FIGURE 65 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 215
TABLE 159 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 161 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 162 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 217
TABLE 163 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 217
TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 218
TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 166 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 219
TABLE 167 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 219
12.4.2 CHINA 219
12.4.2.1 Growing awareness of benefits of leukapheresis to drive market 219
FIGURE 66 CHINA: NUMBER OF CAR-T BASED CLINICAL TRIALS REGISTERED (2013–2020) 220
TABLE 168 CHINA: KEY MACROINDICATORS 220
TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 170 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 171 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 221
TABLE 172 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 222
TABLE 173 CHINA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 174 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 223
TABLE 175 CHINA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 223
12.4.3 JAPAN 223
12.4.3.1 Focus on development of cell therapies to boost market 223
TABLE 176 JAPAN: KEY MACROINDICATORS 224
TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 178 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 179 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 180 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 225
TABLE 181 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 182 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 226
TABLE 183 JAPAN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 226
12.4.4 INDIA 227
12.4.4.1 Rising government investment in healthcare to drive market growth 227
TABLE 184 INDIA: KEY MACROINDICATORS 227
TABLE 185 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 186 INDIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 187 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 228
TABLE 188 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 228
TABLE 189 INDIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 190 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 229
TABLE 191 INDIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 230
12.4.5 AUSTRALIA 230
12.4.5.1 Increasing incidence of blood cancer to drive market 230
TABLE 192 AUSTRALIA: KEY MACROINDICATORS 231
TABLE 193 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 194 AUSTRALIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 195 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 232
TABLE 196 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 232
TABLE 197 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 198 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 233
TABLE 199 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 233
12.4.6 SOUTH KOREA 234
12.4.6.1 Increasing research in cell therapy to fuel market growth 234
TABLE 200 SOUTH KOREA: KEY MACROINDICATORS 234
TABLE 201 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 202 SOUTH KOREA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 203 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 235
TABLE 204 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 235
TABLE 205 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 236
TABLE 206 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 236
TABLE 207 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 237
12.4.7 REST OF ASIA PACIFIC 237
TABLE 208 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 209 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 210 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 238
TABLE 211 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 238
TABLE 212 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 213 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 239
TABLE 214 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 240
12.5 LATIN AMERICA 240
12.5.1 RECESSION IMPACT: LATIN AMERICA 240
TABLE 215 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 216 LATIN AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 217 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 241
TABLE 218 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 242
TABLE 219 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 220 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 243
TABLE 221 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 243
 
12.6 MIDDLE EAST & AFRICA 244
12.6.1 RECESSION IMPACT: MIDDLE EAST & AFRICA 244
TABLE 222 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 223 MIDDLE EAST & AFRICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 224 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 245
TABLE 225 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 245
TABLE 226 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 227 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 246
TABLE 228 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION) 247

13 COMPETITIVE LANDSCAPE 248
13.1 INTRODUCTION 248
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 248
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET 249
13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKOPAKS MARKET 251
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 252
FIGURE 67 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS 252
13.4 COMPETITIVE BENCHMARKING (LEUKAPHERESIS PRODUCTS MARKET) 253
TABLE 229 OVERALL COMPANY FOOTPRINT 253
TABLE 230 COMPANY END USER FOOTPRINT 254
TABLE 231 COMPANY APPLICATION FOOTPRINT 255
TABLE 232 COMPANY REGION FOOTPRINT 256
13.5 MARKET SHARE ANALYSIS (LEUKAPHERESIS PRODUCTS, 2022) 257
TABLE 233 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION 257
FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER (2022) 258
13.6 MARKET SHARE ANALYSIS (LEUKOPAKS, 2022) 258
TABLE 234 LEUKOPAKS MARKET: DEGREE OF COMPETITION 258
FIGURE 69 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2022) 259
13.7 COMPANY EVALUATION MATRIX, 2022 (LEUKAPHERESIS PRODUCTS MARKET) 259
13.7.1 STARS 259
13.7.2 EMERGING LEADERS 260
13.7.3 PERVASIVE PLAYERS 260
13.7.4 PARTICIPANTS 260
FIGURE 70 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION MATRIX (2022) 261
13.8 COMPETITIVE EVALUATION MATRIX FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2022) 262
TABLE 235 LEUKAPHERESIS MARKET: KEY START-UPS/SMES 262
13.8.1 PROGRESSIVE COMPANIES 263
13.8.2 DYNAMIC COMPANIES 263
13.8.3 STARTING BLOCKS 263
13.8.4 RESPONSIVE COMPANIES 263
FIGURE 71 LEUKAPHERESIS MARKET: SMES/START-UPS COMPANY EVALUATION QUADRANT (2022) 264
13.9 COMPETITIVE EVALUATION MATRIX, 2022 (LEUKOPAKS MARKET) 265
13.9.1 STARS 265
13.9.2 EMERGING LEADERS 265
13.9.3 PERVASIVE PLAYERS 265
13.9.4 PARTICIPANTS 265
FIGURE 72 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2022) 266
13.10 COMPETITIVE SCENARIO AND TRENDS 267
TABLE 236 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–AUGUST 2023) 267
TABLE 237 DEALS (JANUARY 2019–AUGUST 2023) 267
TABLE 238 OTHER DEVELOPMENTS (JANUARY 2019–AUGUST 2023) 269
14 COMPANY PROFILES 270
14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET) 270
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
14.1.1 TERUMO BCT 270
TABLE 239 TERUMO BCT: COMPANY OVERVIEW 270
FIGURE 73 TERUMO BCT: COMPANY SNAPSHOT (2022) 271
14.1.2 FRESENIUS SE & CO. KGAA 274
TABLE 240 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 274
FIGURE 74 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2022) 275
14.1.3 HAEMONETICS CORPORATION 279
TABLE 241 HAEMONETICS CORPORATION: COMPANY OVERVIEW 279
FIGURE 75 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022) 280
14.1.4 ASAHI KASEI CORPORATION 284
TABLE 242 ASAHI KASEI CORPORATION: COMPANY OVERVIEW 284
FIGURE 76 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022) 285
14.1.5 MACOPHARMA SA 287
TABLE 243 MACOPHARMA SA: COMPANY OVERVIEW 287
14.1.6 MILTENYI BIOTEC 289
TABLE 244 MILTENYI BIOTEC: COMPANY OVERVIEW 289
14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET) 291
14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD. 291
TABLE 245 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW 291
14.2.2 MEDICA SPA. 292
TABLE 246 MEDICA SPA: COMPANY OVERVIEW 292
14.2.3 PURIBLOOD MEDICAL CO. LTD. 293
TABLE 247 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW 293
14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD. 295
TABLE 248 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW 295
14.2.5 SB-KAWASUMI LABORATORIES, INC. 296
TABLE 249 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW 296
14.2.6 NIKKISO CO., LTD. 297
TABLE 250 NIKKISO CO., LTD.: COMPANY OVERVIEW 297
FIGURE 77 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022) 298
14.2.7 PALL CORPORATION 299
TABLE 251 PALL CORPORATION: COMPANY OVERVIEW 299
14.3 KEY PLAYERS (LEUKOPAKS MARKET) 300
14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 300
TABLE 252 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW 300
FIGURE 78 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022) 301
14.3.2 DISCOVERY LIFE SCIENCES, INC. 304
TABLE 253 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW 304
14.3.3 BIOIVT 307
TABLE 254 BIOIVT: COMPANY OVERVIEW 307
14.3.4 PRECISION FOR MEDICINE, INC. 310
TABLE 255 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW 310
14.3.5 STEMEXPRESS, LLC 311
TABLE 256 STEMEXPRESS, LLC: COMPANY OVERVIEW 311
14.4 OTHER PLAYERS (LEUKOPAKS MARKET) 313
14.4.1 LONZA GROUP AG 313
TABLE 257 LONZA GROUP AG: COMPANY OVERVIEW 313
FIGURE 79 LONZA GROUP AG: COMPANY SNAPSHOT (2022) 314
14.4.2 CALTAG MEDSYSTEMS LIMITED 317
TABLE 258 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW 317
14.4.3 ZENBIO, INC. 318
TABLE 259 ZENBIO, INC.: COMPANY OVERVIEW 318
14.4.4 STEMCELL TECHNOLOGIES 319
14.4.5 TRINA BIOREACTIVES AG 319
14.4.6 ACCEGEN 319
14.4.7 FIRST CHOICE BIO LLC 320
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
 
15 APPENDIX 321
15.1 DISCUSSION GUIDE 321
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 327
15.3 CUSTOMIZATION OPTIONS 329
15.4 RELATED REPORTS 329
15.5 AUTHOR DETAILS 330

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 白血球除去の世界市場予測（～2028）：製品別、白血球アフェレーシス別、疾患別、用途別、エンドユーザー別、地域別(Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
グローバルリサーチ調査資料のイメージグローバルリサーチ調査資料のイメージ
◆関連リサーチレポート◆
  • 気道管理デバイスの世界市場予測（～2028）：種類別、用途別、エンドユーザー別
  • 血管アクセス装置の世界市場予測（～2028）：種類別、用途別、エンドユーザー別 、地域別
  • 患者腫瘍移植/PDXモデルの世界市場予測（～2028）：種類別、移植方法別、腫瘍種類別、用途別、エンドユーザー別
  • 勃起不全デバイスの世界市場予測（～2028）：種類別、ソース別、エンドユーザー別、地域別
  • 血漿分画の世界市場予測（～2028）：製品別、用途別、エンドユーザー別

    • ◆H&Iグローバルリサーチのお客様（例）◆